FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to pharmacology and clinical pharmacology. Method for evaluating the functional activity of glycoprotein-P in the blood-brain barrier according to the pharmacokinetics of its marker substrate fexofenadine includes the intravenous administration of fexofenadine to laboratory animals with the subsequent calculation of the ratio of the area under the curve “concentration of fexofenadine in plasma – time” to the area under the curve “concentration of fexofenadine in the cerebral cortex – time” – AUC0-t-brain/AUC0-t-plasma.
EFFECT: invention can be used with the aim of assessment of the functional activity of glycoprotein-P (Pgp) in the blood-brain barrier for effective and safe pharmacotherapy of a number of neurological diseases.
1 cl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS FOR REDUCTION OF GLYCOPROTEIN-P FUNCTIONAL ACTIVITY AND EXPRESSION | 2017 |
|
RU2649134C1 |
| METHOD TO MODEL CONDITION OF INHIBITION OF FUNCTIONAL ACTIVITY OF GLYCOPROTEIN-P BY LYNESTRENOL IN TRIAL | 2014 |
|
RU2553362C1 |
| METHOD FOR EXPERIMENTAL FINASTERIDE SIMULATION OF INDUCTION OF FUNCTIONAL ACTIVITY OF GLYCOPROTEIN-P | 2012 |
|
RU2504018C1 |
| METHOD OF DETERMINING FUNCTIONAL ACTIVITY OF GLYCOPROTEIN-P | 2015 |
|
RU2587780C1 |
| PHARMACEUTICAL COMPOSITION BASED ON HAEE PEPTIDE FOR TREATING NEURODEGENERATIVE DISEASES | 2019 |
|
RU2709539C1 |
| METHOD FOR SIMULATING INHIBITION STATE OF FUNCTIONAL ACTIVITY OF GLYCOPROTEIN-P WITH DIPEPTIDYL PEPTIDASE 4 INHIBITOR | 2015 |
|
RU2602688C1 |
| METHOD FOR TREATING NEURODEGENERATIVE DISEASES | 2021 |
|
RU2777871C1 |
| THERAPEUTIC USE OF ESLICARBAZEPINE | 2008 |
|
RU2488397C2 |
| METHOD FOR DELIVERING NANOPARTICLES INTENDED FOR THE TRANSPORT OF DRUGS TO THE BRAIN OF MAMMALS THROUGH THE BLOOD-BRAIN BARRIER | 2017 |
|
RU2670091C1 |
| METHOD OF TREATING CEREBRAL OEDEMA IN PATIENTS SUFFERING FROM CHRONIC LIVER DISEASES | 2014 |
|
RU2539139C1 |
